Given that MDS is a myeloid neoplasm with the potential of AML transformation, it suggests that R882 mutations could also confer a higher risk of AML transformation than other DNMT3A mutations in MDS. The gene discussed is DNMT3A; the disease is acute myeloid leukemia.